Bright Biotech Company Profile

Background

Overview

Bright Biotech, established in 2019 and headquartered in Manchester, United Kingdom, is a contract manufacturing and development organization specializing in plant-based expression and production of recombinant proteins. The company leverages chloroplast-based expression systems to produce high-quality and affordable proteins for various applications, including research and development, therapeutics, cosmeceuticals, agri-food, and industrial sectors.

Mission and Vision

Bright Biotech is committed to revolutionizing protein production by providing sustainable, scalable, and cost-effective solutions. Their vision is to facilitate the industrialization of cultivated meat and other biotechnological advancements, thereby contributing to a more sustainable and ethical global food system.

Key Strategic Focus

Core Objectives

• Cost Reduction in Cultivated Meat Production: Addressing the high costs associated with growth factors, which constitute a significant portion of cultivated meat production expenses.

• Sustainable Protein Manufacturing: Utilizing plant-based systems to produce recombinant proteins, reducing reliance on traditional, resource-intensive methods.

Areas of Specialization

• Chloroplast-Based Expression Systems: Harnessing plant chloroplasts to produce recombinant proteins with high yields and scalability.

• Growth Factors Production: Focusing on the production of growth factors essential for cell differentiation and proliferation in cultivated meat and regenerative medicine.

Key Technologies Utilized

• Green2Screen™ Transformation: A proprietary technology that uses CO₂, water, salts, and light to drive protein production in plant chloroplasts.

Primary Markets Targeted

• Cultivated Meat Industry: Providing affordable growth factors to enable scalable and cost-effective meat production.

• Regenerative Medicine: Supplying growth factors to support tissue engineering and cell therapy applications.

Financials and Funding

Funding History

• Seed Funding Round (November 2022): Raised $3.2 million in an oversubscribed round led by FoodLabs, with participation from Big Idea Ventures, CPT Capital, the FoodHack syndicate, and business angels.

Utilization of Capital

• Research and Development: Advancing genetic engineering methods for growth factor production.

• Team Expansion: Recruiting experienced scientists and production experts.

• Manufacturing Scale-Up: Enhancing production capabilities to meet market demand.

Pipeline Development

Key Products

• Recombinant Growth Factors: Essential proteins for cell culture applications in cultivated meat and regenerative medicine.

Development Stages

• Research and Development: Ongoing efforts to optimize protein expression systems.

• Scale-Up: Transitioning from laboratory-scale to industrial-scale production.

Target Conditions

• Cultivated Meat Production: Providing cost-effective growth factors to reduce production costs.

• Regenerative Medicine Applications: Supplying growth factors for tissue engineering and cell therapy.

Anticipated Milestones

• Market Entry: First products from the scalable and sustainable technology expected to be available in 2023.

Technological Platform and Innovation

Proprietary Technologies

• Green2Screen™ Transformation: Utilizes plant chloroplasts to produce proteins using CO₂, water, salts, and light, resulting in high yields and scalability.

Significant Scientific Methods

• Chloroplast-Based Expression: Achieves hyper-expression of proteins, up to 5 grams per kilogram of plant leaves.

• Seed-Based Amplification: Enables 10,000-fold amplification through seeds, facilitating ultra-scalable production.

Leadership Team

• Mohammad El Hajj, Ph.D. – Co-Founder, Chief Executive Officer, and Board Member.

• Tariq Ali, Ph.D. – Co-Founder, Chief Operating Officer, Strategic Advisor, and Board Member.

• Rania Deranieh, Ph.D. – Co-Founder, Chief Product & Innovation Officer, and Chief Technical Officer.

• Anil Day – Co-Founder and Scientific Advisor.

• Farid Khan, Ph.D. – Co-Founder, Financial Advisor, and Board Member.

The leadership team comprises experienced scientists and entrepreneurs with strong academic backgrounds in protein production and cell culture from leading institutions in the UK, USA, Jordan, and Lebanon.

Competitor Profile

Market Insights and Dynamics

• Market Size and Growth Potential: The global cultivated meat industry is projected to reach $116 billion by 2040, driven by increasing demand for sustainable protein sources.

• Industry Trends: Advancements in cellular agriculture and molecular farming are facilitating the development of cost-effective and scalable solutions for protein production.

Competitor Analysis

• Bio-Synthesis: Specializes in manufacturing nucleic acids, peptides, and other molecular biology products.

• Eton Bioscience: Offers DNA sequencing and oligo synthesis solutions.

• Watchmaker Genomics: Develops technologies for reading, writing, and editing nucleic acids.

• Arbor Biosciences: Focuses on genomics, synthetic biology, oligos, and arrays.

These competitors operate in the biotechnology sector, offering various products and services related to molecular biology and genomics.

Strategic Collaborations and Partnerships

• FoodLabs: Led the $3